ArticleISRN oncology2013
CD79B and MYD88 Mutations in Splenic Marginal Zone Lymphoma.
Article in ISRN oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- B-Cell Receptor Signaling and Beyond: The Role of Igα (CD79a)/Igβ (CD79b) in Normal and Malignant B Cells.International journal of molecular sciences · 2023Review
- NF-kB's contribution to B cell fate decisions.Frontiers in immunology · 2023Review
- The role of B cells in the development, progression, and treatment of lymphomas and solid tumors.Advances in immunology · 2022Review
- New Insights into the Biology and Diagnosis of Splenic Marginal Zone Lymphomas.Current oncology (Toronto, Ont.) · 2021Review
- Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond.Annals of lymphoma · 2020Article
- Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Prevalence And Clinical Significance Of OncogenicOncoTargets and therapy · 2019Article
- NF-κB Activation in Lymphoid Malignancies: Genetics, Signaling, and Targeted Therapy.Biomedicines · 2018Review
- Recent advances in understanding the biology of marginal zone lymphoma.F1000Research · 2018Review
- The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP.Oncotarget · 2017Article
- Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.British journal of haematology · 2016Article
- Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation.Haematologica · 2015Article
- Whole exome sequencing of microdissected splenic marginal zone lymphoma: a study to discover novel tumor-specific mutations.BMC cancer · 2015Article
- Toll-like receptor signaling in hematopoietic homeostasis and the pathogenesis of hematologic diseases.Frontiers of medicine · 2015Review
- Mechanisms and consequences of constitutive NF-κB activation in B-cell lymphoid malignancies.Oncogene · 2014Review
- Consequences of the recurrent MYD88(L265P) somatic mutation for B cell tolerance.The Journal of experimental medicine · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mutation status of genes involved in the NF-κB signaling pathway in splenic marginal zone lymphoma was examined. DNA sequence analysis of four genes was performed: CD79A, CD79B, CARD11, and MYD88 that are activated through BCR signaling or Toll-like and interleukin signaling. A single point mutation was detected in the CD79B gene (Y196H) in one of ten SMZL cases. Additionally, one point mutation was identified in the MYD88 gene (L265P) in another SMZL case. No mutations were revealed in CD79A or CARD11 genes in these SMZL cases. Neither were mutations detected in these four genes studied in 13 control MZL samples. Interestingly, the two cases with mutations of CD79B and MYD88 showed increased numbers of immunoblasts spread among the smaller and typical marginal zone lymphoma cells. Although SMZL shows few mutations of NF-κB signaling genes, our results indicate that the presence of these mutations is associated with a higher histological grade.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.